- MGC Pharmaceuticals (MXC) has completed its COVID-19 phase two clinical trial
- The trial saw 50 virus-infected patients treated with MGC’s anti-inflammatory treatment, ArtemiC
- Then the aim of the trial was to test the efficacy and safety of the treatment and evaluate the patient’s recovery rates
- Results of the trial will reported in the next month following an independent technical review and statistical validation of the trial data
- The second wave of the pandemic is again putting increased pressure on a number of healthcare systems around the world
- On the market this afternoon, MGC is up 10 per cent and is trading for 2.2 cents per share
